Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
Fulvestrant maintenance therapy significantly improves progression free survival compared to capecitabine in hormone receptor positive metastatic breast cancer patients
This randomized phase 3 trial in 210 patients with HR+ HER2- metastatic breast cancer compared fulvestrant to capecitabine after first-line …
In a study of 210 patients in China, fulvestrant helped keep cancer from growing longer than capecitabine. Fewer serious side effects occurr…
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
New Drug Helps Some Breast Cancer Patients Live Longer
This systematic review and meta-analysis of 2,808 patients with HR+ HER2- advanced breast cancer found oral SERDs improved progression-free …
New oral pills help some advanced breast cancer patients live longer and fight back against drug resistance by blocking estrogen growth sign…
Research across Hormone Receptor-Positive Breast Cancer
Related studies from across the Hormone Receptor-Positive Breast Cancer family.
Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism
Testicular Adenomatoid Tumor Linked to History of Cryptorchidism
This case report and literature review describes a 58-year-old man with cryptorchidism, male breast cancer, and thymic B2 thymoma who presen…
A new case report highlights a link between undescended testes and certain benign testicular tumors, helping doctors better identify similar…
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer
Artificial Intelligence Shows Promise in Triple-Negative Breast Cancer Care
This narrative synthesis reviews the application of artificial intelligence across radiology, digital pathology, and multi-omics for triple-…
New research shows how artificial intelligence can help identify cancer subtypes and predict treatment responses for patients with triple-ne…
Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging
Case report: Breast cancer spread to small intestine mimics lymphoma
This case report with literature review describes a patient with triple-negative breast cancer who developed small intestinal metastasis pre…
A breast cancer survivor's anemia was caused by a rare small intestine metastasis that looked like lymphoma on scans.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
A single patient remains disease-free after a new chemo-immunotherapy approach for rare breast cancer
This case report describes a 71-year-old woman with triple-negative neuroendocrine breast cancer treated with paclitaxel, cisplatin, and pem…
A 71-year-old woman with rare breast cancer stayed disease-free for a year using a combination of chemotherapy and immunotherapy that doctor…
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
Gut bacteria and diet may hold new keys for triple-negative breast cancer care
This narrative review examines the role of gut microbiome composition, antibiotics, obesity, and dietary modulation in triple-negative breas…
A review explores how gut bacteria, antibiotics, and diet could change treatment for triple-negative breast cancer patients.
Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
Docetaxel chemotherapy linked to rare heart attack in breast cancer patient
This case report and literature review examines acute myocardial infarction following docetaxel chemotherapy in a patient with triple-negati…
A rare heart attack occurred after docetaxel chemotherapy in a patient with triple-negative breast cancer. This case review suggests the dru…
Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
A Hidden Protein in Aggressive Breast Cancer May Unlock New Treatments
This meta-analysis of 12 studies in 1,545 TNBC patients found a pooled NY-ESO-1 expression prevalence of 16.1%. The authors note substantial…
A protein found in about one in six triple-negative breast cancers could open the door to immune-based treatments that target cancer cells w…